Ivonescimab for advanced adrenal gland tumors
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This study tests a new drug called ivonescimab for people with advanced adrenal gland tumors (adrenocortical carcinoma or pheochromocytoma/paraganglioma) that cannot be removed with surgery. The goal is to see if the drug can reduce or stop the growth of the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with adrenocortical carcinoma (ACC) or pheochromocytoma/paraganglioma (PPGL).
- Your tumor is advanced or has spread and cannot be removed with surgery.
- Your tumor has grown in the past 12 months.
- You are generally able to care for yourself (performance status of 0, 1, or 2).
- Your blood counts and organ function are adequate, as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
This trial tests a combination of a new drug, ivonescimab, with chemotherapy given directly into the belly for people whose appendix cancer has spread and cannot be removed with surgery. The goal is to see if this treatment can help control the cancer.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.
This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.
This trial tests a new drug called ivonescimab for people whose glioblastoma has come back after standard treatment. The goal is to see if this drug can help shrink the tumor or slow its growth.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Hear when a new Ivonescimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.